PROGRESS TRIAL
Problem Hypertension in stroke patients
Format Double-blinded multi-center RCT
Treatment Perindopril
Control Placebo
Population TIA/Stroke patients +- HTN
Inclusion criteria Patients were potentially eligible if they had a history of stroke (evidence of an acute disturbance of focal neurological function with symptoms lasting more than 24 h and thought to be due to intracerebral haemorrhage or ischaemia) or transient ischaemic attack (evidence of an acute disturbance of focal neurological or monocular function with symptoms lasting less than 24 h and thought to be due to arterioembolic or thrombotic vascular disease) within the previous 5 years.

Participants were required to have, in the opinion of the responsible physician, no definite indication (such as heart failure) for treatment with an ACE inhibitor and no definite contraindication (such as previous intolerance) to such treatment.

There were no blood pressure entry criteria, although it was recommended that individuals with uncontrolled hypertension receive antihypertensive therapy with agents other than ACE inhibitors before entry to the trial.

It was also recommended that participants should be clinically stable for at least 2 weeks after their most recent vascular event before entry to the study.
Exclusion criteria See exclusion criteria
Follow-up 4 years
Primary endpoint Stroke
Secondary endpoint(s) Total major vascular events
Details -
Brief summary: ACEi reduced recurrent stroke; added indapamide reduced further
PAPER: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.
Date 29 Sep 2001
Journal Lancet. 2001 Sep 29;358(9287):1033-41.
Information In patients with previous stroke or TIAs:
-Reduced risk of stroke in both hypertensive and non-hypertensive individuals
-Combination with indapamide gave lower BPs and greater reductions in stroke
RSS  Subscribe: Latest / All - Designed by Dr James P Howard (Google+)